Abstract
Mycobacterium tuberculosis (the causative agent of tuberculosis), is a stealthy pathogen with a great ability to successfully infect humans and a strong will to stay in the host as long as possible. As much as one admires it as a microbiological entity, M. tuberculosis is also a killer at large responsible for an annual death toll of more than two million people worldwide. Treatment of tuberculosis is a lengthy process that requires multiple drugs for at least six months and although a worldwide health policies established by World Health Organization (WHO) helped reducing the rate of treatment failure, the appearance of novel forms of drug- resistant M. tuberculosis has become a major issue during the last years. The advances in the knowledge of the genetics of this pathogen have allowed for a better understanding of its physiology which in turn helped unveiling the mechanisms of drug action and the ensuing mechanisms of resistance. Surprisingly, it was found that most of the specific anti-tubercular drugs target the synthesis of mycolic acids, long chain fatty acids that are essential components of the cell wall structure. This review highlights the studies on anti-tubercular agents that abrogate the synthesis of mycolic acids with special emphasis on molecules that might be added to the therapeutic weaponry to treat tuberculosis.
Keywords: Tuberculosis, mycolic acid biosynthesis, enoyl-ACP reductase, isoniazid, ethionamide, isoxyl, thiacetazone
Current Respiratory Medicine Reviews
Title: Bringing Down the Wall of the Mycobacterium tuberculosis Fortress: Old and New Inhibitors of Mycolic Acid Biosynthesis
Volume: 5 Issue: 3
Author(s): Hector R.. Morbidoni
Affiliation:
Keywords: Tuberculosis, mycolic acid biosynthesis, enoyl-ACP reductase, isoniazid, ethionamide, isoxyl, thiacetazone
Abstract: Mycobacterium tuberculosis (the causative agent of tuberculosis), is a stealthy pathogen with a great ability to successfully infect humans and a strong will to stay in the host as long as possible. As much as one admires it as a microbiological entity, M. tuberculosis is also a killer at large responsible for an annual death toll of more than two million people worldwide. Treatment of tuberculosis is a lengthy process that requires multiple drugs for at least six months and although a worldwide health policies established by World Health Organization (WHO) helped reducing the rate of treatment failure, the appearance of novel forms of drug- resistant M. tuberculosis has become a major issue during the last years. The advances in the knowledge of the genetics of this pathogen have allowed for a better understanding of its physiology which in turn helped unveiling the mechanisms of drug action and the ensuing mechanisms of resistance. Surprisingly, it was found that most of the specific anti-tubercular drugs target the synthesis of mycolic acids, long chain fatty acids that are essential components of the cell wall structure. This review highlights the studies on anti-tubercular agents that abrogate the synthesis of mycolic acids with special emphasis on molecules that might be added to the therapeutic weaponry to treat tuberculosis.
Export Options
About this article
Cite this article as:
Morbidoni R.. Hector, Bringing Down the Wall of the Mycobacterium tuberculosis Fortress: Old and New Inhibitors of Mycolic Acid Biosynthesis, Current Respiratory Medicine Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339809788922397
DOI https://dx.doi.org/10.2174/157339809788922397 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fighting Diabetes: Lessons from Xenotransplantation and Nanomedicine
Current Pharmaceutical Design High Levels of CD57+CD28- T-Cells, Low T-Cell Proliferation and Preferential Expansion of Terminally Differentiated CD4+ T-Cells in HIVElite Controllers
Current HIV Research Vesicular Carriers for Skin Drug Delivery: The Pheroid™ Technology
Current Pharmaceutical Design Antigen Discovery for Serological Diagnosis of Visceral Leishmaniasis
Current Chemical Biology The Rhesus Macaque Pediatric SIV Infection Model - A Valuable Tool in Understanding Infant HIV-1 Pathogenesis and for Designing Pediatric HIV-1 Prevention Strategies
Current HIV Research Screening of Anti-mycobacterial Phytochemical Compounds for Potential Inhibitors against Mycobacterium Tuberculosis Isocitrate Lyase
Current Topics in Medicinal Chemistry New Opportunities in the Structure-based Design of Anti-Protozoan Agents
Current Topics in Medicinal Chemistry The Use of Proteomics to Study Infectious Diseases
Infectious Disorders - Drug Targets Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry Anti-Infective Peptides to Enhance the Host Innate Response: Design, Development and Delivery
Protein & Peptide Letters Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents Functional Interactions Between B Lymphocytes and the Innate Immune System
Infectious Disorders - Drug Targets Visceral Leishmaniasis: Advances in Treatment
Recent Patents on Anti-Infective Drug Discovery A Systematic Review of Lifestyle Modification and Glucose Intolerance in the Prevention of Type 2 Diabetes
Current Diabetes Reviews Pharmacological and Biological Activities of Xanthones
Anti-Infective Agents in Medicinal Chemistry New Antifolate Inhibitors for Mycobacterium avium
Medicinal Chemistry Closing the Gap: An Atomistic Structural and Functional Perspective of S. <i>mansoni</i> Universal Stress G4LZI3 Protein in Complex with Phenolic Compounds
Current Drug Discovery Technologies Redox Proteins as Targets for Drugs Development Against Pathogens
Current Pharmaceutical Design Parenteral Patent Drug S/GSK1265744 has the Potential to be an Effective Agent in Pre-Exposure Prophylaxis Against HIV Infection
Recent Patents on Anti-Infective Drug Discovery The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued)